Osteoporosis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Bisphosphonates,Parathyroid Hormone Therapy,Calcitonin,Selective Estrogen Inhibitors Modulator (SERM)), By Application (Hospitals,Clinic,Others), Regional Insights and Forecast to 2035

Osteoporosis Treatment Market Overview

The global Osteoporosis Treatment Market is forecast to expand from USD 1531.56 million in 2026 to USD 1616.11 million in 2027, and is expected to reach USD 24159.82 million by 2035, growing at a CAGR of 5.52% over the forecast period.

The global osteoporosis treatment market has experienced significant growth, driven by an aging population and increasing awareness of bone health. In 2024, the market size was valued at approximately USD 12.79 billion and is projected to reach around USD 20.83 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5% from 2024 to 2034. This growth is attributed to advancements in medical technology, rising prevalence of osteoporosis, and increased healthcare spending. In 2023, the North American osteoporosis treatment market was valued at USD 4.15 billion, with projections indicating growth to USD 5.95 billion by 2033. The Asia-Pacific region, particularly Japan, is expected to register the highest CAGR from 2025 to 2030. The market is segmented by drug class, including bisphosphonates, parathyroid hormone therapies, calcitonin, and selective estrogen receptor modulators (SERMs). Bisphosphonates remain the most widely used treatment option, accounting for a significant share of the market.

In the United States, osteoporosis is a major public health concern, affecting approximately 10 million individuals. The market for osteoporosis treatments in the U.S. was valued at USD 4.15 billion in 2024. The prevalence of osteoporosis is higher among postmenopausal women, contributing to the demand for effective treatments. The U.S. market is characterized by a high adoption rate of advanced therapies and a robust healthcare infrastructure, supporting the growth of the osteoporosis treatment market.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Rising demand for pharmaceuticals.
• Major Market Restraint: Demand for refurbished equipment.
• Emerging Trends: Growth in personalized medicines.
• Regional Leadership: North America leads with 41% market share.
• Competitive Landscape: Top companies hold 35% market share.
• Market Segmentation: Bisphosphonates lead with 45% share.
• Recent Developments: FDA approvals increase by 20% in 2024.

Osteoporosis Treatment Market Trends

The osteoporosis treatment market is undergoing significant transformations, fueled by advancements in medical research, technology, and changing patient needs. In 2024, the global market was valued at approximately USD 12.79 billion and is projected to reach around USD 20.83 billion by 2034. Biologic therapies are gaining traction due to their targeted efficacy, with the introduction of multiple denosumab biosimilars expanding treatment options. Advancements in diagnostic technologies, including machine learning models, are improving early detection and enabling personalized treatment plans. Personalized medicine is becoming increasingly important, allowing therapies to be tailored to individual patient profiles to enhance outcomes and reduce side effects. Digital health solutions, such as mobile applications and wearable devices, are facilitating remote monitoring and adherence to treatment regimens.

Postmenopausal osteoporosis remains a major focus, as this group represents a substantial portion of the affected population, with specialized therapies in high demand. Nutraceuticals and plant-based supplements are being explored as adjuncts to conventional treatments, supporting bone health and recovery. Regulatory approvals are driving market expansion, with new medications and therapies gaining access to broader patient populations. There is a growing awareness of osteoporosis in men, prompting research and development of male-focused treatments. Home-based treatment programs, including telemedicine consultations and home medication delivery, are increasing patient convenience and adherence. Finally, the adoption of biosimilars is improving accessibility and affordability, helping to meet the growing global demand for osteoporosis treatments.

Osteoporosis Treatment Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The increasing prevalence of osteoporosis, particularly among the aging population, has led to a higher demand for effective pharmaceutical treatments. In 2024, the global osteoporosis drugs market was valued at USD 15.8 billion and is expected to exhibit growth at a CAGR of 4.6% from 2024 to 2032. This growth is attributed to the ongoing advancements in medical technology, increasing prevalence of osteoporosis, rising geriatric population, increase in the incidences of fractures, and growing emphasis on preventive healthcare.

RESTRAINT

"Demand for refurbished equipment."

The high cost of advanced osteoporosis treatment equipment and medications poses a challenge to market growth. Additionally, limited access to healthcare facilities in certain regions may hinder the widespread adoption of osteoporosis treatments. In 2024, the global osteoporosis drugs market was valued at USD 15.8 billion, with a significant portion allocated to the procurement of advanced medical equipment and pharmaceuticals.

OPPORTUNITY

"Growth in personalized medicines."

Advancements in personalized medicine offer significant opportunities for the osteoporosis treatment market. Tailoring treatments to individual patient profiles can enhance efficacy and reduce adverse effects. In 2024, personalized medicine accounted for approximately 20% of the global pharmaceutical market, with projections indicating continued growth in this segment.

CHALLENGE

"Rising costs and expenditures."

The escalating costs associated with osteoporosis treatments, including medications and diagnostic procedures, present challenges to both patients and healthcare providers. In 2024, the average annual cost of osteoporosis treatment per patient was estimated at USD 1,200, with variations depending on the type of therapy and healthcare setting.

Osteoporosis Treatment Market Segmentation

The osteoporosis treatment market is segmented based on drug type and application.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Bisphosphonates: are the most widely prescribed class of drugs for osteoporosis treatment, accounting for approximately 35% of the global market share in 2023. These drugs work by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk.

Bisphosphonates are expected to dominate the market with a 32.6% share in 2025, driven by their strong bone density improvement properties.

Top 5 Major Dominant Countries in the Bisphosphonates Segment:

• United States: The U.S. accounted for 38.5% of the global bisphosphonates market in 2025 with consistent annual growth.
• Germany: Germany held a 10.2% share, reflecting high adoption in hospital and clinical settings.
• Japan: Japan’s market share reached 8.6% due to increasing osteoporosis prevalence among the elderly.
• France: France contributed 7.4% to the bisphosphonates segment, driven by healthcare awareness campaigns.
• India: India represented 5.3% of the market, supported by rising healthcare infrastructure.

Parathyroid Hormone Therapy: such as teriparatide, stimulate bone formation and are typically used in patients with severe osteoporosis. In 2023, this segment held a market share of around 20%.

Parathyroid hormone therapy accounts for 18.3% of the market in 2025, with increasing demand for anabolic bone treatments.

Top 5 Major Dominant Countries in the Parathyroid Hormone Therapy Segment:

• United States: U.S. leads with 40% market share due to strong adoption of anabolic therapies.
• China: China holds 12% of the market with rising awareness of osteoporosis treatments.
• Germany: Germany accounts for 9%, reflecting high hospital-based therapy usage.
• Brazil: Brazil’s share is 6%, supported by growing geriatric population.
• Australia: Australia contributes 5% to the global market, driven by private healthcare initiatives.

Calcitonin: a hormone that inhibits bone resorption, is used in the treatment of osteoporosis, particularly in postmenopausal women. In 2023, calcitonin accounted for approximately 10% of the market share.

Calcitonin represents 14.2% of the market in 2025, mainly used as an adjunct therapy for osteoporosis patients.

Top 5 Major Dominant Countries in the Calcitonin Segment:

• United States: U.S. holds 35% of the calcitonin market, benefiting from wide clinical adoption.
• France: France represents 15% with strong hospital penetration.
• Italy: Italy accounts for 12% of market share.
• United Kingdom: UK holds 10%, supported by awareness programs.
• Spain: Spain’s share is 8%, reflecting moderate clinical adoption.

Selective Estrogen Receptor Modulators (SERMs): such as raloxifene, mimic estrogen's bone-protective effects without some of its risks. In 2023, SERMs held a market share of about 15%.

SERMs are projected to hold 10.5% of the market in 2025 due to postmenopausal osteoporosis focus.

Top 5 Major Dominant Countries in the SERM Segment:

• United States: U.S. leads with 45% market share, driven by widespread usage in women’s health.
• Canada: Canada accounts for 12% of the SERM market.
• Australia: Australia contributes 10% to the global SERM segment.
• United Kingdom: UK holds 8% with increasing prescriptions for postmenopausal women.
• South Korea: South Korea represents 6% of the market share.

BY APPLICATION

Hospitals: are the primary setting for osteoporosis treatment, accounting for over 50% of the market share in 2023. This is due to the availability of specialized healthcare professionals and advanced diagnostic and therapeutic equipment.

Hospitals account for 40% of the osteoporosis treatment market in 2025, driven by institutional adoption of therapies.

Top 5 Major Dominant Countries in the Hospital Segment:

• United States: U.S. hospital segment holds 45% of the market due to advanced healthcare facilities.
• Germany: Germany contributes 12% with strong hospital infrastructure.
• France: France accounts for 10% of hospital-based treatment usage.
• Japan: Japan holds 9% supported by geriatric patient population.
• United Kingdom: UK contributes 8% of hospital-based market share.

Clinics: including outpatient and specialized bone health centers, constitute approximately 30% of the market share. They offer convenient access to osteoporosis treatments and are increasingly popular among patients.

Clinics are projected to hold 35% of the market in 2025 with growing outpatient care services.

Top 5 Major Dominant Countries in the Clinic Segment:

• United States: U.S. clinics represent 40% of the market, driven by outpatient therapy services.
• China: China holds 15% of the clinic segment with increasing healthcare access.
• India: India accounts for 12%, supported by private clinics.
• Brazil: Brazil contributes 10% of the clinic market share.
• Mexico: Mexico holds 7%, reflecting moderate outpatient care adoption.

Others: settings, such as home care and long-term care facilities, represent about 20% of the market share. The growth of this segment is driven by the aging population and the preference for home-based care.

The “Others” segment, including home care and online delivery, represents 25% of the market in 2025.

Top 5 Major Dominant Countries in the “Others” Segment:

• United States: U.S. holds 30% in the “Others” category due to telemedicine adoption.
• Germany: Germany accounts for 12% market share.
• Japan: Japan holds 10% driven by home healthcare services.
• France: France represents 8% of this segment.
• United Kingdom: UK contributes 7% to “Others” market share.

Osteoporosis Treatment Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

led the global osteoporosis treatment market with a 41% market share in 2023. The region's dominance is attributed to advanced healthcare infrastructure, high healthcare expenditure, and a significant aging population.

The North American osteoporosis treatment market is valued at USD 5.5 billion in 2025 with a strong adoption of hospital and clinic-based therapies.

North America - Major Dominant Countries:

• United States: Market size USD 3.5 billion, share 63%, CAGR 5.2%, led by advanced healthcare infrastructure.
• Canada: Market size USD 1.2 billion, share 22%, CAGR 4.8% with growing geriatric population.
• Mexico: Market size USD 0.8 billion, share 15%, CAGR 5.0% driven by clinic-based treatments.

EUROPE

held a market share of approximately 30% in 2023. The region's strong healthcare systems and increasing awareness about osteoporosis contribute to its substantial market presence.

• Europe holds significant market presence with a focus on hospital-based and postmenopausal therapies.

Europe - Major Dominant Countries:

• Germany: Market size USD 1.5 billion, share 25%, CAGR 5.5% with strong hospital adoption.
• France: Market size USD 1.2 billion, share 20%, CAGR 4.9% with growing awareness programs.
• Italy: Market size USD 1.0 billion, share 17%, CAGR 4.7% due to hospital and clinic adoption.
• United Kingdom: Market size USD 0.9 billion, share 15%, CAGR 4.6%.
• Spain: Market size USD 0.8 billion, share 13%, CAGR 4.5%.

ASIA-PACIFIC

region is anticipated to expand at the fastest CAGR of 6.3% during the forecast period. The growing elderly population and improving healthcare access in countries like Japan, China, and India are driving this growth.

Asia-Pacific market is expanding rapidly due to aging populations and improving healthcare infrastructure.

Asia - Major Dominant Countries:

• China: Market size USD 1.8 billion, share 30%, CAGR 6.3%.
• India: Market size USD 1.4 billion, share 23%, CAGR 6.0%.
• Japan: Market size USD 1.2 billion, share 20%, CAGR 5.8%.
• South Korea: Market size USD 0.5 billion, share 8%, CAGR 5.5%.
• Australia: Market size USD 0.4 billion, share 7%, CAGR 5.2%.

MIDDLE EAST & AFRICA

region accounted for about 10% of the global market share in 2023. Factors such as rising healthcare investments and increasing prevalence of osteoporosis are contributing to market expansion in this region.

Middle East and Africa market is growing steadily with increased awareness and private healthcare adoption.

Middle East and Africa - Major Dominant Countries:

• Saudi Arabia: Market size USD 0.5 billion, share 25%, CAGR 4.5%.
• South Africa: Market size USD 0.4 billion, share 20%, CAGR 4.2%.
• United Arab Emirates: Market size USD 0.35 billion, share 18%, CAGR 4.0%.
• Egypt: Market size USD 0.3 billion, share 15%, CAGR 3.8%.
• Nigeria: Market size USD 0.25 billion, share 12%, CAGR 3.7%.

List of Top Osteoporosis Treatment Companies

• Actavis Plc.
• GlaxoSmithKline Pharmaceutical Ltd.
• Hoffmann La Roche Ltd.
• Allergan Plc
• Novartis AG
• Amgen, Inc.
• Merck & Co AG
• Eli Lilly and Company
• Pfizer, Inc.
• Novo Nordisk A/S
• Teva Pharmaceuticals Industries Ltd.

GlaxoSmithKline Pharmaceutical Ltd. – Holds approximately 18% of the global osteoporosis treatment market share, with a strong portfolio including bisphosphonates and selective estrogen receptor modulators (SERMs). In 2024, GSK supplied over 25 million doses worldwide.

Amgen, Inc. – Accounts for around 15% of the global market share, primarily driven by biologic therapies such as denosumab. In 2024, Amgen’s osteoporosis treatments were administered to over 20 million patients globally.

Investment Analysis and Opportunities

The osteoporosis treatment market offers substantial investment opportunities driven by the rising prevalence of osteoporosis, an aging global population, and increasing awareness of bone health. In 2024, approximately 10 million individuals in the United States were diagnosed with osteoporosis, highlighting the large patient base and potential for expansion. Investors are increasingly focusing on the development of novel therapies, including biologics, bisphosphonates, and selective estrogen receptor modulators, which accounted for over 70% of the treatment market in 2024. Personalized medicine presents a major investment avenue, with tailored therapies projected to capture about 20% of the global pharmaceutical market by 2025. Digital health solutions, including telemedicine platforms and remote monitoring devices, are attracting capital, as over 35% of patients now utilize these tools for treatment adherence and bone health tracking.

Additionally, the biosimilar segment is expanding rapidly, with approvals for denosumab biosimilars increasing by 20% in 2024, providing opportunities for cost-effective alternatives and wider patient access. Emerging markets in Asia-Pacific and Latin America are drawing investment due to growing elderly populations and improved healthcare infrastructure, with North America maintaining approximately 41% of the global market share. Strategic partnerships, mergers, and acquisitions are becoming increasingly common, allowing companies to consolidate resources and accelerate the development of innovative osteoporosis therapies. Nutraceuticals and plant-based adjunct therapies are also gaining attention, with research and development investments rising by 15% in 2024. Investors are leveraging these trends to tap into both mature and emerging markets, ensuring sustained growth opportunities in the osteoporosis treatment landscape.

New Product Development

The osteoporosis treatment market is witnessing significant innovation with the development of new products aimed at improving efficacy, safety, and patient adherence. In 2024, several denosumab biosimilars, including denosumab-bbdz and denosumab-dssb, were launched, expanding treatment options and enhancing accessibility for millions of patients worldwide. Pharmaceutical companies are also investing in novel drug delivery systems, such as subcutaneous injections and oral formulations, which simplify administration and improve compliance. Parathyroid hormone analogs and next-generation selective estrogen receptor modulators (SERMs) are being introduced with enhanced bone-forming capabilities and reduced side effects. Additionally, combination therapies that integrate bisphosphonates with nutraceuticals or calcium and vitamin D supplements are gaining traction to provide comprehensive bone health support.

Digital integration is a key focus, with smart pill dispensers, mobile applications, and wearable devices being developed to monitor patient adherence and track treatment outcomes in real time. The introduction of personalized medicine approaches is influencing product design, allowing treatments to be tailored based on genetic, lifestyle, and clinical factors. Innovative diagnostic tools, including advanced imaging and predictive algorithms, are being paired with treatment products to enable early detection and optimized therapy selection. Emerging markets are also witnessing the launch of cost-effective biosimilars and generics, catering to the increasing elderly population and the growing prevalence of osteoporosis. Overall, new product development is centered on enhancing patient-centric care, expanding treatment accessibility, and integrating technology to support long-term bone health management.

Five Recent Developments

• In 2024, the FDA approved denosumab-bbdz and denosumab-dssb, expanding the availability of biosimilar treatments for osteoporosis.
• The National Institute for Health and Care Excellence (NICE) in the UK approved the use of abaloparatide for postmenopausal women at high risk of fractures, providing a new treatment option.
• In 2025, Biocon Biologics received U.S. FDA approval for two denosumab biosimilars, enhancing its presence in the osteoporosis treatment market.
• A study published in 2025 demonstrated that XGBoost machine learning models achieved 91% accuracy in predicting osteoporosis risk, highlighting advancements in diagnostic technologies.
• The introduction of home-based osteoporosis treatment programs has increased patient access to care, particularly in rural and underserved areas.

Report Coverage of Osteoporosis Treatment Market

The Osteoporosis Treatment Market report provides a comprehensive analysis of the global industry, covering market size, trends, dynamics, and forecasts to 2034. The report examines key drivers, restraints, opportunities, and challenges shaping the market landscape, offering detailed insights into the factors influencing growth. It includes an in-depth regional analysis, highlighting North America’s 41% market share, Europe’s 30% share, the Asia-Pacific region’s rapid expansion, and the emerging Middle East & Africa market. The report also presents a thorough segmentation analysis by drug type—bisphosphonates, parathyroid hormone therapy, calcitonin, and selective estrogen receptor modulators (SERMs)—and by application, including hospitals, clinics, and other care settings. In addition, the report profiles leading companies such as GlaxoSmithKline Pharmaceutical Ltd. and Amgen, Inc., providing data on market share, product portfolios, and recent developments, including the launch of denosumab biosimilars and novel therapies.

The report highlights market trends, including the rise of biologics, personalized medicine, digital health integration, and nutraceutical adoption, while also analyzing emerging opportunities in biosimilars, home-based treatment programs, and underserved regions. Investment insights, new product developments, regulatory approvals, and technological innovations are detailed to provide a holistic view of the market. By combining quantitative data, qualitative analysis, and forward-looking forecasts, the report offers actionable intelligence for stakeholders, including pharmaceutical companies, healthcare providers, investors, and policymakers, to make informed decisions and strategically navigate the evolving osteoporosis treatment market.

Osteoporosis Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1531.56 Million in 2026
Market Size Value By	USD 24159.82 Million by 2035
Growth Rate	CAGR of 5.52% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Bisphosphonates Parathyroid Hormone Therapy Calcitonin Selective Estrogen Inhibitors Modulator (SERM) By Application : Hospitals Clinic Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample